Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of MORAb-003 in platinum-sensitive epithelial ovarian cancer at first relapse
NL-OMON30586Phase 2Active, not recruiting
- Sponsor
- Morphotek
- Start
- Oct 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of farletuzumab in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 arms), sponsored by Morphotek. Primary endpoints: CA125 response in single-agent MORAb-003 arm, Objective and biomarker response with MORAb-003 plus chemotherapy and 2 more. Started Oct 2007; status: active, not recruiting.
02
Drugs
farletuzumab
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NL-OMON30586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30586.